Mats W. Johansson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mats W. Johansson has a total of 256 co-authors. Here are the top co-authors by number of shared publications:
Nizar N. Jarjour
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin, Madison, WI, USA
16 shared publicationsDeane F. Mosher
Morgridge Institute for Research Madison Wisconsin USA
15 shared publicationsKenneth Söderhäll
15 shared publications- Stephane Esnault
Université de Lille, Inserm, Centre Hospitalier Universitaire (CHU) Lille, U1286, Institute for Translational Research in Inflammation , Lille F-59000
12 shared publications - Elizabeth A. Becky Kelly
Pulmonary and Critical Care Sections of Department of Medicine, University of Wisconsin , Madison, WI 53792
8 shared publications Steven R. Barthel
Department of Biomolecular, University of Wisconsin-Madison, 4285A Medical Sciences Center, 1300 University Avenue, Madison, WI 53706-1532, USA
6 shared publications
Latest Publications
- 3 July 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (7)
Rhinovirus infection may contribute to esophageal inflammation in eosinophilic esophagitis
Eosinophil esophagitis (EoE) shares many epidemiologic and pathophysiologic characteristics with other allergic diseases, especially allergic asthma. Because rhinovirus (RV) infection is known to contribute to inflammation in allergic asthma, we sought to investigate whether RV might also contribute to esophageal inflammation in EoE through epithelial activation. In vitro cultures of primary esophageal epithelial cells and a human nontransformed immortalized esophageal epithelial cell line (EPC2-hTERT) grown submerged or at air-liquid interface were infected with RV-A1a or RV-A16. In addition, we added interleukin (IL)-13 to mimic EoE conditions. RV-binding receptors, RV replication, and interferon lambda-1 (IFNL1) response to infection were measured. RNA sequencing (RNA-seq) on RV-infected EPC2-hTERT cultures was performed for Gene Ontology analysis and compared with published RNA-seq data of esophageal biopsies from EoE patients. Both RV receptors were expressed by esophageal cells. After infection, we observed higher RV viral gene expression, indicative of active replication. IL-13 had little effect on replication in monolayers but was required in air-liquid interface for replication to occur. Interferon lambda-1 (IFNL1) messenger RNA was induced by RV-A1a in both cell types and IFNL1 protein was increased in IL-13–treated EPC2-hTERT monolayers. Gene Ontology analysis of our in vitro experimental model highlighted virus-induced processes and increased IFN activity. In addition, we found overlapping genes between our RNA-seq results of EPC2-hTERT cells and publicly available RNA-seq data from esophageal biopsies of patients with EoE versus healthy control donors. Our data suggest the possibility that viruses such as RV may contribute to esophageal inflammation and play an important role in the inception and/or persistence of EoE.
- 3 July 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (7)
Rhinovirus infection may contribute to esophageal inflammation in eosinophilic esophagitis
Eosinophil esophagitis (EoE) shares many epidemiologic and pathophysiologic characteristics with other allergic diseases, especially allergic asthma. Because rhinovirus (RV) infection is known to contribute to inflammation in allergic asthma, we sought to investigate whether RV might also contribute to esophageal inflammation in EoE through epithelial activation. In vitro cultures of primary esophageal epithelial cells and a human nontransformed immortalized esophageal epithelial cell line (EPC2-hTERT) grown submerged or at air-liquid interface were infected with RV-A1a or RV-A16. In addition, we added interleukin (IL)-13 to mimic EoE conditions. RV-binding receptors, RV replication, and interferon lambda-1 (IFNL1) response to infection were measured. RNA sequencing (RNA-seq) on RV-infected EPC2-hTERT cultures was performed for Gene Ontology analysis and compared with published RNA-seq data of esophageal biopsies from EoE patients. Both RV receptors were expressed by esophageal cells. After infection, we observed higher RV viral gene expression, indicative of active replication. IL-13 had little effect on replication in monolayers but was required in air-liquid interface for replication to occur. Interferon lambda-1 (IFNL1) messenger RNA was induced by RV-A1a in both cell types and IFNL1 protein was increased in IL-13–treated EPC2-hTERT monolayers. Gene Ontology analysis of our in vitro experimental model highlighted virus-induced processes and increased IFN activity. In addition, we found overlapping genes between our RNA-seq results of EPC2-hTERT cells and publicly available RNA-seq data from esophageal biopsies of patients with EoE versus healthy control donors. Our data suggest the possibility that viruses such as RV may contribute to esophageal inflammation and play an important role in the inception and/or persistence of EoE.
- Open Access
- 12 May 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Increased potential for atherogenic changes in asthma: evidence from transcriptomic studies of arterial endothelial cells
Asthma is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), yet the mechanistic pathways underlying this relationship remain poorly defined. Clinical ASCVD is initiated by arterial injury, with endothelial dysfunction representing the earliest detectable stage. We aimed to characterize the differential transcriptomic response of naïve arterial endothelial cells (AECs) exposed to serum from individuals with and without asthma, using a novel stem cell-derived AEC model. Pluripotent-derived naïve AECs were incubated with serum from individuals with asthma or healthy controls for 6 and 24 h. RNA sequencing was performed on AEC lysates, genes were compared between asthma and healthy control serum treatments, and differentially expressed genes were identified. Functional enrichment and pathway analyses were conducted using DAVID, ShinyGO, and STRING. Statistical significance was determined using false discovery rate (FDR)-adjusted p values to account for multiple comparisons. After 6 h of exposure to asthma serum, genes associated with biological processes of endothelial cell proliferation, angiogenesis, migration, and focal adhesion assembly (FDR-adjusted p = 0.04) were significantly enriched among upregulated genes (compared to among all genes, p = 0.0002, 0.004, and 0.04, respectively). Enriched pathways included adhesion junction, mitogen-activated protein kinase, neurotrophin, hypoxia-inducible factor-1, and Wnt signaling (p = 0.00001, 0.00004, 0.002, 0.002, 0.00001, and 0.01). At both 6 and 24 h, pathways related to lipid and atherosclerosis (p = 0.02), epidermal growth factor (EGF) receptor (p = 0.03 and 0.02 at 6 and 24 h), advanced glycation end products (AGE)-receptor for AGEs (RAGE) (p = 0.03 and 0.001), and Ras (p = 0.04 and 0.03) and Rap1 (p = 0.04 and 0.046) signaling were upregulated. Fibronectin (FN1), a central hub in the STRING network, was the highest expressed among upregulated genes at 6 h. Other central genes included EGF, vascular endothelial growth factor A and fibroblast growth factor receptor 1. Serum from individuals with asthma, compared to serum from healthy donors, induced gene expression alterations in a novel model of naïve AECs. These transcriptional changes are consistent with early cellular injury, including pathways of lipid-atherosclerosis, endothelial cell activation, adhesion, and AGE-RAGE signaling. These findings indicate that circulating factors in asthma activate arterial endothelial cells to promote early vascular injury.
- 12 May 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessIncreased potential for atherogenic changes in asthma: evidence from transcriptomic studies of arterial endothelial cells
Asthma is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), yet the mechanistic pathways underlying this relationship remain poorly defined. Clinical ASCVD is initiated by arterial injury, with endothelial dysfunction representing the earliest detectable stage. We aimed to characterize the differential transcriptomic response of naïve arterial endothelial cells (AECs) exposed to serum from individuals with and without asthma, using a novel stem cell-derived AEC model. Pluripotent-derived naïve AECs were incubated with serum from individuals with asthma or healthy controls for 6 and 24 h. RNA sequencing was performed on AEC lysates, genes were compared between asthma and healthy control serum treatments, and differentially expressed genes were identified. Functional enrichment and pathway analyses were conducted using DAVID, ShinyGO, and STRING. Statistical significance was determined using false discovery rate (FDR)-adjusted p values to account for multiple comparisons. After 6 h of exposure to asthma serum, genes associated with biological processes of endothelial cell proliferation, angiogenesis, migration, and focal adhesion assembly (FDR-adjusted p = 0.04) were significantly enriched among upregulated genes (compared to among all genes, p = 0.0002, 0.004, and 0.04, respectively). Enriched pathways included adhesion junction, mitogen-activated protein kinase, neurotrophin, hypoxia-inducible factor-1, and Wnt signaling (p = 0.00001, 0.00004, 0.002, 0.002, 0.00001, and 0.01). At both 6 and 24 h, pathways related to lipid and atherosclerosis (p = 0.02), epidermal growth factor (EGF) receptor (p = 0.03 and 0.02 at 6 and 24 h), advanced glycation end products (AGE)-receptor for AGEs (RAGE) (p = 0.03 and 0.001), and Ras (p = 0.04 and 0.03) and Rap1 (p = 0.04 and 0.046) signaling were upregulated. Fibronectin (FN1), a central hub in the STRING network, was the highest expressed among upregulated genes at 6 h. Other central genes included EGF, vascular endothelial growth factor A and fibroblast growth factor receptor 1. Serum from individuals with asthma, compared to serum from healthy donors, induced gene expression alterations in a novel model of naïve AECs. These transcriptional changes are consistent with early cellular injury, including pathways of lipid-atherosclerosis, endothelial cell activation, adhesion, and AGE-RAGE signaling. These findings indicate that circulating factors in asthma activate arterial endothelial cells to promote early vascular injury.
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (3)
Cytokines and growth factors produced and released by human eosinophils: lessons from cocultures and omics studies
Besides their largely specific and abundant toxic granule proteins, their Charcot-Leyden crystals, DNA traps, and the release of leukotrienes, human eosinophils are often seen as affecting the immune response and tissue remodeling due to the release of numerous types of cytokines and growth factors. However, the extent of release and the functionality of such mediators, particularly from human eosinophils, remains uncertain. We review the literature focused on cocultures of human eosinophils with other cell types to identify possible cytokines and growth factors secreted by eosinophils and their function(s) on epithelial cells, fibroblasts, lymphocytes, and endothelial cells. Models of coculture include direct cell-to-cell contact, separation with filters, and the use of eosinophil-conditioned media. These models identified cytokines and growth factors as potential eosinophilic factors affecting the behavior of other cell types. In multiple published transcriptome data sets, the expression of these factors in eosinophils was confirmed using human blood and tissue eosinophils, which also allowed us to identify additional potentially important eosinophilic products. The findings in this review support the idea that human eosinophils remain effector cells via their release of toxic proteins (ie EPX/eosinophil peroxidase, RNASE3/eosinophil cationic protein, PRG2/eosinophil major basic protein), Charcot-Leyden crystals of galectin-10, DNA, and leukotrienes, and they produce and release a set of cytokines and growth factors to affect their surroundings.
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (3)
Cytokines and growth factors produced and released by human eosinophils: lessons from cocultures and omics studies
Besides their largely specific and abundant toxic granule proteins, their Charcot-Leyden crystals, DNA traps, and the release of leukotrienes, human eosinophils are often seen as affecting the immune response and tissue remodeling due to the release of numerous types of cytokines and growth factors. However, the extent of release and the functionality of such mediators, particularly from human eosinophils, remains uncertain. We review the literature focused on cocultures of human eosinophils with other cell types to identify possible cytokines and growth factors secreted by eosinophils and their function(s) on epithelial cells, fibroblasts, lymphocytes, and endothelial cells. Models of coculture include direct cell-to-cell contact, separation with filters, and the use of eosinophil-conditioned media. These models identified cytokines and growth factors as potential eosinophilic factors affecting the behavior of other cell types. In multiple published transcriptome data sets, the expression of these factors in eosinophils was confirmed using human blood and tissue eosinophils, which also allowed us to identify additional potentially important eosinophilic products. The findings in this review support the idea that human eosinophils remain effector cells via their release of toxic proteins (ie EPX/eosinophil peroxidase, RNASE3/eosinophil cationic protein, PRG2/eosinophil major basic protein), Charcot-Leyden crystals of galectin-10, DNA, and leukotrienes, and they produce and release a set of cytokines and growth factors to affect their surroundings.
- 8 January 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (2)
Association between absolute blood eosinophil count and carotid plaque and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA)
Prior studies have demonstrated associations between eosinophil activation products and incident stroke. We investigated whether circulating eosinophil concentration is associated with imaging markers of atherosclerotic cardiovascular disease (ASCVD), analyzing 2 arterial beds (carotid artery plaque [CAP] and coronary artery calcium [CAC]) in the Multi-Ethnic Study of Atherosclerosis (MESA). The MESA enrolled individuals aged 45 to 84, without ASCVD at baseline. ASCVD risk factors, blood eosinophils, CAP presence/score (0 to 12), and CAC presence/Agatston score were measured at MESA Exam No. 5. Using logistic and linear regression analyses, the relationships between blood eosinophils, CAP or CAC presence, or scores (log[score + 1]), adjusted for confounders, were evaluated. The 2,166 participants were a mean (standard deviation [SD]) 69.6 (9.3) years old, 53% female, 29% Hispanic, 28% Black, 1% Chinese American. The eosinophil count was median (interquartile range) 0.10 (0.10, 0.20)×103/μl, CAP score 2 (0, 4), and CAC score 45 (0, 292) Agatston units. In risk-factor adjusted models, increased blood eosinophil count (per 1 SD [0.15 × 103/μl]) was associated with log scores of CAP (β: 0.05 [95% confidence interval 0.02 to 0.08, P = 0.001) or CAC (β: 0.11, [0.01 to 0.21], P = 0.03). Similar associations were observed for eosinophils and CAP (odds ratio [OR]: 1.12, [1.01 to 1.25], P = 0.03) and CAC (OR: 1.15, [1.02 to 1.30], P = 0.02) presence. In conclusion, in a large, multiethnic US cohort, blood eosinophils were independently linked to imaging atherosclerosis measures in 2 arterial distributions. These data suggest potential roles of eosinophilic inflammation in atherosclerosis.
- 8 January 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (2)
Association between absolute blood eosinophil count and carotid plaque and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA)
Prior studies have demonstrated associations between eosinophil activation products and incident stroke. We investigated whether circulating eosinophil concentration is associated with imaging markers of atherosclerotic cardiovascular disease (ASCVD), analyzing 2 arterial beds (carotid artery plaque [CAP] and coronary artery calcium [CAC]) in the Multi-Ethnic Study of Atherosclerosis (MESA). The MESA enrolled individuals aged 45 to 84, without ASCVD at baseline. ASCVD risk factors, blood eosinophils, CAP presence/score (0 to 12), and CAC presence/Agatston score were measured at MESA Exam No. 5. Using logistic and linear regression analyses, the relationships between blood eosinophils, CAP or CAC presence, or scores (log[score + 1]), adjusted for confounders, were evaluated. The 2,166 participants were a mean (standard deviation [SD]) 69.6 (9.3) years old, 53% female, 29% Hispanic, 28% Black, 1% Chinese American. The eosinophil count was median (interquartile range) 0.10 (0.10, 0.20)×103/μl, CAP score 2 (0, 4), and CAC score 45 (0, 292) Agatston units. In risk-factor adjusted models, increased blood eosinophil count (per 1 SD [0.15 × 103/μl]) was associated with log scores of CAP (β: 0.05 [95% confidence interval 0.02 to 0.08, P = 0.001) or CAC (β: 0.11, [0.01 to 0.21], P = 0.03). Similar associations were observed for eosinophils and CAP (odds ratio [OR]: 1.12, [1.01 to 1.25], P = 0.03) and CAC (OR: 1.15, [1.02 to 1.30], P = 0.02) presence. In conclusion, in a large, multiethnic US cohort, blood eosinophils were independently linked to imaging atherosclerosis measures in 2 arterial distributions. These data suggest potential roles of eosinophilic inflammation in atherosclerosis.
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (8) , 1515-1518
Proteomic Analysis of Asthma Airway Inflammation after Allergen Challenge: A Heterogeneous Response
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (8) , 1515-1518
Proteomic Analysis of Asthma Airway Inflammation after Allergen Challenge: A Heterogeneous Response
- Open Access
- 12 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (12) , 1247-1250
Identification of the Cytokines, Growth Factors and Their Receptors Expressed by Human Blood Eosinophils: A Transcriptomics Approach
- 12 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (12) , 1247-1250
Open AccessIdentification of the Cytokines, Growth Factors and Their Receptors Expressed by Human Blood Eosinophils: A Transcriptomics Approach
- Open Access
Oncostatin‐M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma
- 17 June 2024
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 185 (11) , 1033-1047
Eosinophil-Epithelial Cell Interactions in Asthma
Background: Eosinophils have numerous roles in type 2 inflammation depending on their activation states in the blood and airway or after encounter with inflammatory mediators. Airway epithelial cells have a sentinel role in the lung and, by instructing eosinophils, likely have a foundational role in asthma pathogenesis. Summary: In this review, we discuss various topics related to eosinophil-epithelial cell interactions in asthma, including the influence of eosinophils and eosinophil products, e.g., granule proteins, on epithelial cell function, expression, secretion, and plasticity; the effects of epithelial released factors, including oxylipins, cytokines, and other mediators on eosinophils, e.g., on their activation, expression, and survival; possible mechanisms of eosinophil-epithelial cell adhesion; and the role of intra-epithelial eosinophils in asthma. Key Messages: We suggest that eosinophils and their products can have both injurious and beneficial effects on airway epithelial cells in asthma and that there are bidirectional interactions and signaling between eosinophils and airway epithelial cells in asthma.
- 17 June 2024
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 185 (11) , 1033-1047
Eosinophil-Epithelial Cell Interactions in Asthma
Background: Eosinophils have numerous roles in type 2 inflammation depending on their activation states in the blood and airway or after encounter with inflammatory mediators. Airway epithelial cells have a sentinel role in the lung and, by instructing eosinophils, likely have a foundational role in asthma pathogenesis. Summary: In this review, we discuss various topics related to eosinophil-epithelial cell interactions in asthma, including the influence of eosinophils and eosinophil products, e.g., granule proteins, on epithelial cell function, expression, secretion, and plasticity; the effects of epithelial released factors, including oxylipins, cytokines, and other mediators on eosinophils, e.g., on their activation, expression, and survival; possible mechanisms of eosinophil-epithelial cell adhesion; and the role of intra-epithelial eosinophils in asthma. Key Messages: We suggest that eosinophils and their products can have both injurious and beneficial effects on airway epithelial cells in asthma and that there are bidirectional interactions and signaling between eosinophils and airway epithelial cells in asthma.
- 1 June 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 326 (6) , L796-L804
A novel DNase assay reveals low DNase activity in severe asthma
We developed a new DNase assay and used it to show that DNase activity is impaired in asthma airways.
- 1 June 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 326 (6) , L796-L804
A novel DNase assay reveals low DNase activity in severe asthma
We developed a new DNase assay and used it to show that DNase activity is impaired in asthma airways.
- Open Access
- 4 September 2023
- Published by Wiley in Physiological Reports
- Vol. 11 (17) , e15814
Decreased plasma cartilage acidic protein 1 in COVID‐19
Cartilage acidic protein‐1 (CRTAC1) is produced by several cell types, including Type 2 alveolar epithelial (T2AE) cells that are targeted by SARS‐CoV2. Plasma CRTAC1 is known based on proteomic surveys to be low in patients with severe COVID‐19. Using an ELISA, we found that patients treated for COVID‐19 in an ICU almost uniformly had plasma concentrations of CRTAC1 below those of healthy controls. Magnitude of decrease in CRTAC1 distinguished COVID‐19 from other causes of acute respiratory decompensation and correlated with established metrics of COVID‐19 severity. CRTAC1 concentrations below those of controls were found in some patients a year after hospitalization with COVID‐19, long COVID after less severe COVID‐19, or chronic obstructive pulmonary disease. Decreases in CRTAC1 in severe COVID‐19 correlated (r = 0.37, p = 0.0001) with decreases in CFP (properdin), which interacts with CRTAC1. Thus, decreases of CRTAC1 associated with severe COVID‐19 may result from loss of production by T2AE cells or co‐depletion with CFP. Determination of significance of and reasons behind decreased CRTAC1 concentration in a subset of patients with long COVID will require analysis of roles of preexisting lung disease, impact of prior acute COVID‐19, age, and other confounding variables in a larger number of patients.
- 4 September 2023
- Published by Wiley in Physiological Reports
- Vol. 11 (17) , e15814
Open AccessDecreased plasma cartilage acidic protein 1 in COVID‐19
Cartilage acidic protein‐1 (CRTAC1) is produced by several cell types, including Type 2 alveolar epithelial (T2AE) cells that are targeted by SARS‐CoV2. Plasma CRTAC1 is known based on proteomic surveys to be low in patients with severe COVID‐19. Using an ELISA, we found that patients treated for COVID‐19 in an ICU almost uniformly had plasma concentrations of CRTAC1 below those of healthy controls. Magnitude of decrease in CRTAC1 distinguished COVID‐19 from other causes of acute respiratory decompensation and correlated with established metrics of COVID‐19 severity. CRTAC1 concentrations below those of controls were found in some patients a year after hospitalization with COVID‐19, long COVID after less severe COVID‐19, or chronic obstructive pulmonary disease. Decreases in CRTAC1 in severe COVID‐19 correlated (r = 0.37, p = 0.0001) with decreases in CFP (properdin), which interacts with CRTAC1. Thus, decreases of CRTAC1 associated with severe COVID‐19 may result from loss of production by T2AE cells or co‐depletion with CFP. Determination of significance of and reasons behind decreased CRTAC1 concentration in a subset of patients with long COVID will require analysis of roles of preexisting lung disease, impact of prior acute COVID‐19, age, and other confounding variables in a larger number of patients.